The Moderna vaccine uses mRNA containing the Zika genetic sequence to incite an immune response in the patient.
Under the agreement, the ASPR’s Biomedical Advanced Research and Development Authority will provide Moderna with technical assistance, oversight, funding, toxicology studies, vaccine formulation and manufacturing.
“BARDA is taking a three-pronged approach to combat Zika, developing vaccines, diagnostics and technologies that will protect the blood supply,” said Richard Hatchett, MD, acting director of BARDA. “Today’s agreement with Moderna expands and diversifies our portfolio of candidate vaccines and improves our chances of having a vaccine to provide protection to people and halt the spread of the Zika virus.”
More articles on the Zika virus:
After Zika funds fail, Florida congressman brings mosquitoes to House floor
Zika can live in the eyes, tears of mice
Which states have the most Zika cases?
